HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Lisata Therapeutics (NASDAQ:LSTA) and maintained a price target of $15, indicating confidence in the company's future performance.
September 18, 2024 | 10:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating for Lisata Therapeutics and maintained a $15 price target, suggesting positive expectations for the company's stock performance.
The reiteration of a Buy rating and maintenance of a $15 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and could lead to an increase in the stock price of Lisata Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100